Ixekizumab for the treatment of psoriasis: an update on new data since first approval

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension

(2018) A Kimball et al.   ACTA DERMATO-VENEREOLOGICA

Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab

(2018) R.B. Warren et al.   BRITISH JOURNAL OF DERMATOLOGY

Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)

(2018) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis

(2018) C. Ryan et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)

(2018) R.G. Langley et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials

(2018) Lian Cui et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis

(2018) Kristian Reich et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Commentary: The Corrona-National Psoriasis Foundation Psoriasis Registry

(2018) Bruce Strober   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation

(2018) Scott M. Whitlock et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Maintenance of Skin Clearance With Ixekizumab Treatment of Psoriasis: Three-Year Results From the UNCOVER-3 Study

(2018) Craig Leonardi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis

(2018) Anne M. Loos et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3

(2018) Alexander Egeberg et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Inflammatory bowel disease events after exposure to the IL-17 inhibitors, secukinumab and ixekizumab: A post-marketing analysis from the RADAR (Research on Adverse Drug events And Reports) Program

(2018) Kelsey A. Orrell et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis

(2018) Claus Zachariae et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Paradoxical Eczematous Reaction to Ixekizumab

(2018) M Munera-Campos et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis

(2018) Therezia Bokor-Billmann et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials

(2018) R G Langley et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials

(2018) Philip Mease et al.   ARTHRITIS CARE & RESEARCH

Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study

(2018) G. Deza et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1)

(2017) Shinichi Imafuku et al.   JOURNAL OF DERMATOLOGY

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis

(2017) Zarif K. Jabbar-Lopez et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1)

(2017) Désirée van der Heijde et al.   JOURNAL OF RHEUMATOLOGY

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data

(2017) Bruce Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

(2017) A. Blauvelt et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3

(2017) C.L. Leonardi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials

(2017) L. Guenther et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials

(2017) C. Paul et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)

(2017) A. Menter et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

(2017) Peter Nash et al.   LANCET

Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies

(2017) Christopher E.M. Griffiths et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents

(2016) Andrea Chiricozzi et al.   Expert Opinion On Drug Safety

Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3)

(2016) Kristian Reich et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

(2016) Hidehisa Saeki et al.   JOURNAL OF DERMATOLOGY

Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials

(2016) Alexandra B. Kimball et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3

(2016) P. van de Kerkhof et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Treatment outcomes with ixekizumab in patients with moderate-to-severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies

(2016) A.B. Gottlieb et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis

(2016) April W. Armstrong et al.   JAMA Dermatology

Ixekizumab for treatment of psoriasis

(2015) Beatrice Dyring-Andersen et al.   Expert Review of Clinical Immunology

Psoriasis

(2015) Wolf-Henning Boehncke et al.   LANCET

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Assessment of ixekizumab, an interleukin-17A monoclonal antibody, for potential effects on reproduction and development, including immune system function, in cynomolgus monkeys

(2015) D.O. Clarke et al.   REPRODUCTIVE TOXICOLOGY

Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis

(2014) H. Saeki et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Heritability of psoriasis in a large twin sample

(2013) A.S. Lønnberg et al.   BRITISH JOURNAL OF DERMATOLOGY

The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity

(2011) Wolf-Henning Boehncke et al.   EXPERIMENTAL DERMATOLOGY

Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in Germany

(2010) M Augustin et al.   ACTA DERMATO-VENEREOLOGICA

Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study

(2010) O. Ahlehoff et al.   JOURNAL OF INTERNAL MEDICINE

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE